Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

Diabetes Care(2022)10.2337/dc22-0866Source: DataRank Database

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS is a research paper published in Diabetes Care (2022). On theSindex it has a DataRank of 0. It has been cited 58 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access58 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)Impact (FWCI 7.04)OA: bronzeTopics (44)Linked Datasets (4)DataCite Reuse (4)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Meir Schechter ORCID,Taha Sen ORCID,Priya Vart ORCID,Brendon L. Neuen ORCID,Bruce Neal ORCID

Live enrichment

PubMed:36134918 PMC:PMC9862371 OpenAlex:https://openalex.org/W4297891186

NHLBI NIH HHS

Grant: OT2 HL161847

NIDDK NIH HHS

Grant: U01 DK100846

NIDDK NIH HHS

Grant: U2C DK114886

NIDDK NIH HHS

Grant: U54 DK083912

European Commission

Grant: 115974

Biomarker Enterprise to Attack DKD - Sofia ref.: 115974

National Institutes of Health

Grant: 4R01HL109568-04

Human Platelet Defects in Transcription Factor RUNX1 Haplodeficiency

National Institutes of Health

Grant: 5U01DK100846-13

CureGN-Penn PCC

National Institutes of Health

Grant: 2U54DK083912-06

Nephrotic Syndrome Rare Disease Clinical Research Network

National Institutes of Health

Grant: 3UL1TR002319-02S1

Transform Dissemination and Implementation Science in CTSA Programs

National Institutes of Health

Grant: 3OT2HL161847-01S3

OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core

National Institutes of Health

Grant: 1U2CDK114886-01

Central Hub for Kidney Precision Medicine

National Institutes of Health

Grant: 1R01MD014712-01

Prediction of Chronic Kidney Disease by Simulation Modeling to Improve the Health of Minority Populations

Janssen Research and Development

CDC HHS

FWCI

7.04

Citation Percentile

1.0%

Influential Citations

Citation Trend

2023

2024

2025

2026

bronzeLicense: https://www.diabetesjournals.org/journals/pages/license

journalhttps://diabetesjournals.org/care/article-pdf/45/11/2644/690145/dc220866.pdf

BRONZEhttps://diabetesjournals.org/care/article-pdf/45/11/2644/690145/dc220866.pdf

publisherhttps://diabetesjournals.org/care/article-pdf/45/11/2644/690145/dc220866.pdf

publisherhttps://diabetesjournals.org/care/article-pdf/45/11/2644/716206/dc220866.pdf

journalhttps://doi.org/10.2337/dc22-0866

Fields of Study

Adipokines, Inflammation, and Metabolic DiseasesDiabetes Treatment and ManagementChemokine receptors and signalingMedicine03 medical and health sciences0302 clinical medicine

MeSH Terms

CanagliflozinSodium-Glucose Transporter 2 InhibitorsCardiovascular DiseasesDiabetes Mellitus, Type 2HumansKidneyInterleukin-6

Keywords

CanagliflozinMedicineRenal functionKidney diseaseInternal medicineType 2 diabetesPlaceboDiabetes mellitusEndocrinologyPathologyClinical Trials and Supportive ActivitiesRenal and urogenital61032 Biomedical and Clinical SciencesCardiovascularKidneyanzsrc-for: 32 Biomedical and Clinical SciencesClinical ResearchHumansPathophysiology/Complications3202 Clinical SciencesSodium-Glucose Transporter 2 Inhibitorsanzsrc-for: 42 Health sciencesInterleukin-6Diabetesanzsrc-for: 11 Medical and Health SciencesDiabetes Mellitus, Type 2Cardiovascular Diseases6.1 Pharmaceuticalsanzsrc-for: 3202 Clinical SciencesType 2

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials

10.6084/m9.figshare.24630303.v1figshare

Additional file 1 of The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials

10.6084/m9.figshare.24630303figshare

Additional file 1 of Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial

10.6084/m9.figshare.24655913.v1figshare

10.6084/m9.figshare.24655913figshare

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

FAIR Checklist

Authors (12)

Funding (14 grants)

Impact

Open Access

Topics

Linked Datasets (4)

Annotations (Europe PMC)